

**B-LCL-CDG1 | 302012**

**Description**  
B-LCL-CDG1 (CDG) PMM2-CDG EBV B .  
EBV B-LCL-CDG1 \*PMM2\* . , PMM2 ,

2(PM

**Organism**

**Tissue**

**Disease**

**Metastatic site** (EBV B-LCL; )

**Applications** CDG . ( : B ). . . . HLA .

**Gender**

**Ethnicity**

**Morphology**

**Cell type** B

**Growth properties** ,

**Citation** B-LCL-CDG1( 302012)

**Biosafety level** 2

**NCBI\_TaxID** 9606

**CellosaurusAccession**

**GMO Status** GMO-S2: B-LCL (EBNA-1/-2/-3, LMP-1/-2) EBV . EBV 2

**B-LCL-CDG1 | 302012**

**Viruses** : EBV

**Culture Medium** RPMI 1640, w: 2.0mM , w: 2.0g/L NaHCO3( 820700a)

**Supplements** 10% FBS

**Subculturing** .  $2 \times 10^5$  /ml ,  $1 \times 10^5 \sim 5 \times 10^5$  /ml .

**Fluid renewal**

**Freeze medium** (FBS ) + 10% DMSO , CM-1(Cytion 800100)

**Thawing and Culturing Cells**

1. .
2. -150°C , 3 .
3. 37°C 40~60 .
4. , 70% .
5. 8ml 15ml .
6. 300 x g 3 .
7. 10ml . T25 , T25
8. .

**Incubation Atmosphere** 37°C, 5% CO<sub>2</sub> .

**Flask Coating**

**B-LCL-CDG1 | 302012**

**Freezing  
Procedure**

-78°C

**Shipping  
Conditions**

-78°C

**Storage  
Conditions**

-150°C -196°C .80°C

/ / HLA

**Sterility**

PCR